Polish PNH patients monitored on ravulizumab: real-life results revealed

NCT ID NCT06633536

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 28 times

Summary

This study looks at how well ravulizumab works for people with paroxysmal nocturnal hemoglobinuria (PNH) in everyday medical practice in Poland. Researchers will track 64 adults already receiving the drug, measuring blood markers and how many blood transfusions they need. The goal is to see if real-world results match those from clinical trials.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Research Site

Bialystok, Poland
Research Site

Brzozów, Poland
Research Site

Bydgoszcz, Poland
Research Site

Gdansk, Poland
Research Site

Krakow, Poland
Research Site

Lodz, Poland
Research Site

Lublin, Poland
Research Site

Opole, Poland
Research Site

Szczecin, Poland
Research Site

Warsaw, Poland
Research Site

Wałbrzych, Poland

Conditions

Explore the condition pages connected to this study.

PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA